الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 241 |  |  |
| | | from | 241 | | |
Abstract
Renal cell carcinoma (RCC) is the commonest histologic subtype
of renal tumors accounting for about 85%. Globally it accounts for3% of
all malignancies in adult. In Egypt, Kidney cancer represent about 11% of
malignancies of urinary system and 1.78% of total malignancies with
RCC accounting for more than 60% of them.
Up to 30% of organ confined RCC develop metastasis or
recurrence during follow up time. Also, due to asymptomatic nature of
the disease, about 17% of cases are diagnosed at advanced stage with
very limited therapeutic modalities and short over-all survival. Thus,
there is an urgent need to identify specific biomarkers that can be used for
early diagnosis, prognosis and to tailor treatment strategies for RCC
patients.
Some studied reported important role of STAT3-HIF1α pathway in
development and progression of RCC. Therefore, targeting this pathway
may represent a promising therapeutic modality for RCC patients.
The aim of this study was to study the immunohistochemical
expression results of pSTAT3, HIF1α and VEGF in RCC and correlate
their expression with available clinicopathologic parameters and survival
data.
This retrospective case control study was conducted on 89 renal
specimens including 58 cases of RCC, 14 cases end stage kidney (ESKD)
and 17 cases of non-neoplastic tissue adjacent to tumors. All specimens
were obtained from Egyptian patients.
In this study a significant statistical difference could be detected
between pSTAT3, HIF1α and VEGF expression in RCC and ESKD
groups with a higher expression among RCC cases.